179 related articles for article (PubMed ID: 11027133)
1. Crystal structure of human cathepsin V.
Somoza JR; Zhan H; Bowman KK; Yu L; Mortara KD; Palmer JT; Clark JM; McGrath ME
Biochemistry; 2000 Oct; 39(41):12543-51. PubMed ID: 11027133
[TBL] [Abstract][Full Text] [Related]
2. The crystal structure of human cathepsin L complexed with E-64.
Fujishima A; Imai Y; Nomura T; Fujisawa Y; Yamamoto Y; Sugawara T
FEBS Lett; 1997 Apr; 407(1):47-50. PubMed ID: 9141479
[TBL] [Abstract][Full Text] [Related]
3. Azepanone-based inhibitors of human cathepsin L.
Marquis RW; James I; Zeng J; Trout RE; Thompson S; Rahman A; Yamashita DS; Xie R; Ru Y; Gress CJ; Blake S; Lark MA; Hwang SM; Tomaszek T; Offen P; Head MS; Cummings MD; Veber DF
J Med Chem; 2005 Nov; 48(22):6870-8. PubMed ID: 16250645
[TBL] [Abstract][Full Text] [Related]
4. Crystal structure of the parasite protease inhibitor chagasin in complex with a host target cysteine protease.
Ljunggren A; Redzynia I; Alvarez-Fernandez M; Abrahamson M; Mort JS; Krupa JC; Jaskolski M; Bujacz G
J Mol Biol; 2007 Aug; 371(1):137-53. PubMed ID: 17561110
[TBL] [Abstract][Full Text] [Related]
5. Crystal structure of porcine cathepsin H determined at 2.1 A resolution: location of the mini-chain C-terminal carboxyl group defines cathepsin H aminopeptidase function.
Guncar G; Podobnik M; Pungercar J; Strukelj B; Turk V; Turk D
Structure; 1998 Jan; 6(1):51-61. PubMed ID: 9493267
[TBL] [Abstract][Full Text] [Related]
6. Structural basis of inhibition of cysteine proteases by E-64 and its derivatives.
Matsumoto K; Mizoue K; Kitamura K; Tse WC; Huber CP; Ishida T
Biopolymers; 1999; 51(1):99-107. PubMed ID: 10380357
[TBL] [Abstract][Full Text] [Related]
7. Exploring inhibitor binding at the S' subsites of cathepsin L.
Chowdhury SF; Joseph L; Kumar S; Tulsidas SR; Bhat S; Ziomek E; Ménard R; Sivaraman J; Purisima EO
J Med Chem; 2008 Mar; 51(5):1361-8. PubMed ID: 18278855
[TBL] [Abstract][Full Text] [Related]
8. The crystal structure of human cathepsin F and its implications for the development of novel immunomodulators.
Somoza JR; Palmer JT; Ho JD
J Mol Biol; 2002 Sep; 322(3):559-68. PubMed ID: 12225749
[TBL] [Abstract][Full Text] [Related]
9. Development of peptidomimetics with a vinyl sulfone warhead as irreversible falcipain-2 inhibitors.
Ettari R; Nizi E; Di Francesco ME; Dude MA; Pradel G; Vicík R; Schirmeister T; Micale N; Grasso S; Zappalà M
J Med Chem; 2008 Feb; 51(4):988-96. PubMed ID: 18232656
[TBL] [Abstract][Full Text] [Related]
10. Crystal structure of human cathepsin S.
McGrath ME; Palmer JT; Brömme D; Somoza JR
Protein Sci; 1998 Jun; 7(6):1294-302. PubMed ID: 9655332
[TBL] [Abstract][Full Text] [Related]
11. Specificity determinants of human cathepsin s revealed by crystal structures of complexes.
Pauly TA; Sulea T; Ammirati M; Sivaraman J; Danley DE; Griffor MC; Kamath AV; Wang IK; Laird ER; Seddon AP; Ménard R; Cygler M; Rath VL
Biochemistry; 2003 Mar; 42(11):3203-13. PubMed ID: 12641451
[TBL] [Abstract][Full Text] [Related]
12. Toxoplasma gondii cathepsin L is the primary target of the invasion-inhibitory compound morpholinurea-leucyl-homophenyl-vinyl sulfone phenyl.
Larson ET; Parussini F; Huynh MH; Giebel JD; Kelley AM; Zhang L; Bogyo M; Merritt EA; Carruthers VB
J Biol Chem; 2009 Sep; 284(39):26839-50. PubMed ID: 19596863
[TBL] [Abstract][Full Text] [Related]
13. Use of papain as a model for the structure-based design of cathepsin K inhibitors: crystal structures of two papain-inhibitor complexes demonstrate binding to S'-subsites.
LaLonde JM; Zhao B; Smith WW; Janson CA; DesJarlais RL; Tomaszek TA; Carr TJ; Thompson SK; Oh HJ; Yamashita DS; Veber DF; Abdel-Meguid SS
J Med Chem; 1998 Nov; 41(23):4567-76. PubMed ID: 9804696
[TBL] [Abstract][Full Text] [Related]
14. Human cathepsin V functional expression, tissue distribution, electrostatic surface potential, enzymatic characterization, and chromosomal localization.
Brömme D; Li Z; Barnes M; Mehler E
Biochemistry; 1999 Feb; 38(8):2377-85. PubMed ID: 10029531
[TBL] [Abstract][Full Text] [Related]
15. Biotin-labelled peptidyl diazomethane inhibitors derived from the substrate-like sequence of cystatin: targeting of the active site of cruzipain, the major cysteine proteinase of Trypanosoma cruzi.
Lalmanach G; Mayer R; Serveau C; Scharfstein J; Gauthier F
Biochem J; 1996 Sep; 318 ( Pt 2)(Pt 2):395-9. PubMed ID: 8809025
[TBL] [Abstract][Full Text] [Related]
16. Lysosomal cysteine proteases (cathepsins): promising drug targets.
Turk D; Guncar G
Acta Crystallogr D Biol Crystallogr; 2003 Feb; 59(Pt 2):203-13. PubMed ID: 12554931
[TBL] [Abstract][Full Text] [Related]
17. Identification and characterization of a cathepsin L-like cysteine protease from Gnathostoma spinigerum.
Kongkerd N; Uparanukraw P; Morakote N; Sajid M; McKerrow JH
Mol Biochem Parasitol; 2008 Aug; 160(2):129-37. PubMed ID: 18554733
[TBL] [Abstract][Full Text] [Related]
18. Crystal structure of human cathepsin K complexed with a potent inhibitor.
McGrath ME; Klaus JL; Barnes MG; Brömme D
Nat Struct Biol; 1997 Feb; 4(2):105-9. PubMed ID: 9033587
[No Abstract] [Full Text] [Related]
19. Elastin degradation by cathepsin V requires two exosites.
Du X; Chen NL; Wong A; Craik CS; Brömme D
J Biol Chem; 2013 Nov; 288(48):34871-81. PubMed ID: 24121514
[TBL] [Abstract][Full Text] [Related]
20. Discovery of selective and nonpeptidic cathepsin S inhibitors.
Irie O; Ehara T; Iwasaki A; Yokokawa F; Sakaki J; Hirao H; Kanazawa T; Teno N; Horiuchi M; Umemura I; Gunji H; Masuya K; Hitomi Y; Iwasaki G; Nonomura K; Tanabe K; Fukaya H; Kosaka T; Snell CR; Hallett A
Bioorg Med Chem Lett; 2008 Jul; 18(14):3959-62. PubMed ID: 18572405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
